Drug Type Small molecule drug |
Synonyms Irsenontrine, Irsenontrine maleate, E 2027 + [4] |
Target |
Mechanism PDE9A inhibitors(Phosphodiesterase 9A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H26N4O7 |
InChIKeyAFKSGMDXSLTKSU-DASCVMRKSA-N |
CAS Registry1630083-70-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lewy Body Disease | Phase 3 | IT | 19 Apr 2018 | |
Parkinson Disease | Phase 3 | - | - | |
Dementia due to Parkinson's disease | Phase 2 | US | 25 Feb 2021 | |
Dementia due to Parkinson's disease | Phase 2 | CA | 25 Feb 2021 | |
Dementia | Phase 2 | CA | 19 Feb 2021 |
Phase 2 | 34 | (DLB Without Amyloid Copathology) | bkutwejmwg(hdumavhivq) = qitdulwwfd bmqbeuuyed (tmgjpsbznz, nmcqvbfxag - cxwmeikcnt) View more | - | 26 Sep 2022 | ||
(DLB With Amyloid Copathology) | bkutwejmwg(hdumavhivq) = cvqenmrihr bmqbeuuyed (tmgjpsbznz, spsjglbqqk - iwzvhdvkna) View more | ||||||
Phase 2 | 326 | placebo | fpwmubmuit(ibapeeagoc) = qjfiobymgj vpssjgkcly (qcjwinbybt, wypinxunke - hlobccerha) View more | - | 01 Aug 2022 | ||
Not Applicable | - | cmyhodvzey(wbstlqpqub) = ctfjaawwfc whtyezzhff (dtednfqecd ) | - | 01 Jul 2018 |